Oxford Drug Design is an emerging leader in AI-based drug discovery. An advanced spinout from Oxford University, we design and develop highly innovative small-molecule drugs against cancer based on our differentiated dual core competences platform. We combine deep and extensive expertise in the versatile tRNA synthetases target family with our pioneering AI/ML computational capability. This leads to novel mechanisms of action. Our validated platform has been funded by $8m of international grants and allows to accelerate the discovery and development of our discovery programmes focused on oncology.